27
total announcements
524804.BO · 15 min delayed
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has scheduled its 39th Annual General Meeting (AGM) to be held on August 27, 2026, through video conferencing. The notice and integrated annual report for the financial year 2025-26 will be sent to shareholders via email and made available on the company's website.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has announced the schedule of an earnings call to be held on August 6, 2026, to discuss the unaudited financial results for the first quarter ended June 30, 2026.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 to consider and approve Intimation of Board Meeting, including the Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2026.
Aurobindo Pharma Ltd
Aurobindo Pharma has signed a non-exclusive voluntary license agreement with MSD to supply generic alimatravir to 129 Low- & Middle-Income Countries (LMICs) for HIV prevention, subject to regulatory approvals.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has acquired 80% ownership in A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA for an enterprise value of USD 17 million. A1 Biochem Group is a Contract Research Organization (CRO) providing high-quality chemistry services to pharmaceutical companies, biotechs, and academic institutions.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has received ANVISA approval for its biosimilars manufacturing facility in Hyderabad, strengthening its capability to supply biosimilar products to the Brazilian and broader Latin American markets.
Aurobindo Pharma Ltd
Aurobindo Pharma USA, a wholly-owned subsidiary of Aurobindo Pharma Ltd, has received U.S. Federal Trade Commission (FTC) approval to acquire Lannett Company LLC for $250 million. This acquisition significantly expands Aurobindo's product offering in complex, non-opioid controlled substances and adds a U.S.-based manufacturing facility. The transaction, expected to close by end of June 2026, is anticipated to be immediately accretive to the Aurobindo Group's earnings per share. It is also projected to generate meaningful cost efficiencies, SG&A synergies, and enhance the company's differentiated pipeline for sustainable long-term growth.